Kalaris Therapeutics Inc KLRS · Stock Open Kalaris Therapeutics Inc in new tab
Analyst price targets
Recent rating changes, newest first
Kalaris Therapeutics Inc Analysis (KLRS)
Is Kalaris Therapeutics Inc a good investment? Kalaris Therapeutics Inc (KLRS) is currently trading at 2.13 USD. Market analysts have a consensus price target of 18.71 USD. This suggests a potential upside from current levels.
Earnings Schedule: Kalaris Therapeutics Inc is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -1.66.
Investor FAQ
Does Kalaris Therapeutics Inc pay a dividend?
No, it does not currently pay a dividend.
What asset class is Kalaris Therapeutics Inc?
Kalaris Therapeutics Inc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -2.02.
Company Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 16, 2025 | 1:25 |
Community Discussion